Skip to main content

Cholesterol Med Fenofibrate Might Slow Vision Loss in People With Diabetes

Medically reviewed by Carmen Pope, BPharm. Last updated on June 25, 2024.

By Dennis Thompson HealthDay Reporter

TUESDAY, June 25, 2024 -- A well-established cholesterol-lowering drug appears to significantly slow the progression of a diabetes-related eye disease, a new trial shows.

Fenofibrate (Tricor) has been approved since 2004 as a means of lowering cholesterol. Now, this new study shows that fenofibrate also can reduce the progression of diabetic retinopathy by 27% compared to placebo.

The findings were published June 21 in the journal NEJM Evidence and presented simultaneously at the American Diabetes Association’s annual meeting in Orlando, Fla.

“Diabetic retinopathy remains a leading cause of visual loss and we need simple strategies that can be widely used to reduce the progression of diabetic eye disease,” said researcher David Preiss, an associate professor at Oxford Population Health in the UK.

The results from the new trial “suggest that fenofibrate may provide a valuable addition to treat people with diabetic retinopathy,” Preiss added in a meeting news release.

Diabetic retinopathy occurs when elevated blood sugar levels damage blood vessels in the back of the eye. The vessels start to swell and leak, eventually leading to blurry vision, blank spots and blindness.

For this study, researchers recruited 1,151 adults in Scotland who had developed early diabetic retinopathy or macular degeneration. They were randomly assigned to take either fenofibrate tablets or a placebo.

Over four years, nearly 23% of people taking fenofibrate had their eye disease worsen, compared with 29% on a placebo, results show.

Fenofibrate also cut the risk of developing macular edema, which is a potentially harmful swelling in the retina.

Participants’ progress will continue to be tracked, to better understand the long-term effects of fenofibrate on health, researchers said.

Sources

  • American Diabetes Association, news release, June 21, 2024

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted June 2024

Read this next

Ozempic Could Curb Progression of Diabetes-Linked Liver Disease

MONDAY, Sept. 16, 2024 -- Fatty liver disease linked to diabetes and obesity can easily progress to liver cirrhosis, but new research suggests that GLP-1 medicines like Ozempic...

Weekly Insulin Injections As Effective for Diabetes as Daily Shots, Studies Show

WEDNESDAY, Sept. 11, 2024 -- Weekly insulin shots can help control both type 1 and type 2 diabetes as well as daily injections do, a pair of clinical trials have found. A new...

Diabetes Can Sometimes Lead to Gum Disease

WEDNESDAY, Sept. 11, 2024 -- People with diabetes are more prone to gum disease, due to the damage the chronic illness does to small blood vessels, a new study warns. Diabetics...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.